
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Omeprazole
Therapeutic Area : Undisclosed
Study Phase : Undisclosed
Sponsor : BIO-CAT
Deal Size : Inapplicable
Deal Type : Inapplicable
Omeprazole Effect on Postprandial Amino Acids After Mixed Meal
Details : Omeprazole is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of unspecified medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 26, 2025
Lead Product(s) : Omeprazole
Therapeutic Area : Undisclosed
Highest Development Status : Undisclosed
Sponsor : BIO-CAT
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Brain Canada
Deal Size : $0.1 million
Deal Type : Funding
Brain Cancer Canada Grants $100K to McGill for Pediatric Cancer Research
Details : The funding will be used to advance a gene therapy treatment for pediatric high-grade gliomas (pHGG), an aggressive and often fatal group of brain cancers.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
May 12, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Brain Canada
Deal Size : $0.1 million
Deal Type : Funding

McGill, industry, CQDM and Brain Canada collaborate for drug discovery
Details : The funding aims to advance the discovery of investigational products that have made significant progress in development and could help treat insomnia and neuropathic pain.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
July 03, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : P3 - Whey
Therapeutic Area : Undisclosed
Study Phase : Undisclosed
Recipient : BIO-CAT
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : P3 - Whey is a drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
July 24, 2023
Lead Product(s) : P3 - Whey
Therapeutic Area : Undisclosed
Highest Development Status : Undisclosed
Recipient : BIO-CAT
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Coenzyme Q10,Caspofungin
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Undisclosed
Sponsor : Clarus
Deal Size : $40.8 million
Deal Type : Licensing Agreement
Details : Under the licensing agreement Clarus will develop and commercialize McGill’s proprietary technology designed to treat conditions associated with CoQ10 deficiencies in humans with Coenzyme-Q10 (Ubiquinone).
Product Name : Ubiquinone
Product Type : Enzyme
Upfront Cash : $0.4 million
September 16, 2021
Lead Product(s) : Coenzyme Q10,Caspofungin
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Undisclosed
Sponsor : Clarus
Deal Size : $40.8 million
Deal Type : Licensing Agreement

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Enoxacin
Therapeutic Area : Neurology
Study Phase : Phase I/ Phase II
Sponsor : Weizmann Institute of Science | Apotex Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Enoxacin for Amyotrophic Lateral Sclerosis (ALS)
Details : Enoxacin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Amyotrophic Lateral Sclerosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 12, 2021
Lead Product(s) : Enoxacin
Therapeutic Area : Neurology
Highest Development Status : Phase I/ Phase II
Sponsor : Weizmann Institute of Science | Apotex Inc
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Probiotic
Therapeutic Area : Undisclosed
Study Phase : Phase I/ Phase II
Sponsor : LALLEMAND HEALTH SOLUTIONS
Deal Size : Inapplicable
Deal Type : Inapplicable
Probiotics for Enhanced Tissue Carotenoid Status in Premenopausal Women
Details : This is a Probiotic drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Probiotic
Upfront Cash : Inapplicable
August 12, 2020
Lead Product(s) : Probiotic
Therapeutic Area : Undisclosed
Highest Development Status : Phase I/ Phase II
Sponsor : LALLEMAND HEALTH SOLUTIONS
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Vitamin D
Therapeutic Area : Undisclosed
Study Phase : Undisclosed
Recipient : Dubai Health Authority
Deal Size : Inapplicable
Deal Type : Inapplicable
Vitamin D Regulates the Expression of Glucocorticoid Receptors in Blood of Severe Asthmatic Patients
Details : Vitamin D is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
June 23, 2020
Lead Product(s) : Vitamin D
Therapeutic Area : Undisclosed
Highest Development Status : Undisclosed
Recipient : Dubai Health Authority
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : Discovery
Recipient : Neurasic Therapeutic
Deal Size : Undisclosed
Deal Type : Partnership
Details : Neurasic’s potential drug therapy targets acid-sensing ion channels (ASICs), a gene family of neuronal receptors activated by protons that play a role in multiple neurological disorders.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
June 04, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Discovery
Recipient : Neurasic Therapeutic
Deal Size : Undisclosed
Deal Type : Partnership
